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Bayesian networks (BNs) are machine-learning–based computational models that visualize
causal relationships and provide insight into the processes underlying disease progression,
closely resembling clinical decision-making. Preoperative identification of patients at risk for
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lymph node metastasis (LNM) is challenging in endometrial cancer, and although several
biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of
this study was to develop and externally validate a preoperative BN to predict LNM and out-
come in endometrial cancer patients.
Methods and findings
Within the European Network for Individualized Treatment of Endometrial Cancer (ENI-
TEC), we performed a retrospective multicenter cohort study including 763 patients, median
age 65 years (interquartile range [IQR] 58–71), surgically treated for endometrial cancer
between February 1995 and August 2013 at one of the 10 participating European hospitals.
A BN was developed using score-based machine learning in addition to expert knowledge.
Our main outcome measures were LNM and 5-year disease-specific survival (DSS). Preop-
erative clinical, histopathological, and molecular biomarkers were included in the network.
External validation was performed using 2 prospective study cohorts: the Molecular Markers
in Treatment in Endometrial Cancer (MoMaTEC) study cohort, including 446 Norwegian
patients, median age 64 years (IQR 59–74), treated between May 2001 and 2010; and the
PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study cohort, including 384 Dutch
patients, median age 66 years (IQR 60–73), treated between September 2011 and Decem-
ber 2013. A BN called ENDORISK (preoperative risk stratification in endometrial cancer)
was developed including the following predictors: preoperative tumor grade; immunohisto-
chemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, and L1
cell adhesion molecule (L1CAM); cancer antigen 125 serum level; thrombocyte count; imag-
ing results on lymphadenopathy; and cervical cytology. In the MoMaTEC cohort, the area
under the curve (AUC) was 0.82 (95% confidence interval [CI] 0.76–0.88) for LNM and 0.82
(95% CI 0.77–0.87) for 5-year DSS. In the PIPENDO cohort, the AUC for 5-year DSS was
0.84 (95% CI 0.78–0.90). The network was well-calibrated. In the MoMaTEC cohort, 249
patients (55.8%) were classified with <5% risk of LNM, with a false-negative rate of 1.6%. A
limitation of the study is the use of imputation to correct for missing predictor variables in the
development cohort and the retrospective study design.
Conclusions
In this study, we illustrated how BNs can be used for individualizing clinical decision-making
in oncology by incorporating easily accessible and multimodal biomarkers. The network
shows the complex interactions underlying the carcinogenetic process of endometrial can-
cer by its graphical representation. A prospective feasibility study will be needed prior to
implementation in the clinic.
Author summary
Why was this study done?
• Bayesian networks are graphical networks that are based on machine learning and can
be used for prediction purposes without the need to have values for all predictor vari-
ables available for each patient.
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• Approximately 10% of patients with endometrial cancer have lymph node metastasis.
• The risk of lymph node metastasis and poor outcome differs substantially between
individuals.
• Preoperative identification of patients at risk for lymph node metastasis and poor out-
come allows tailoring of individualized treatment.
What did the researched do and find?
• A Bayesian network to predict the risk of lymph node metastasis and survival was con-
structed with data from a retrospective multicenter development cohort from 10 centers
across Europe (n = 763).
• The predictive capability of the final network was tested in 2 external cohorts from the
Netherlands (PIpelle Prospective ENDOmetrial carcinoma [PIPENDO], n = 384) and
from Norway (Molecular Markers in Treatment in Endometrial Cancer [MoMaTEC], n
= 446).
What do these findings mean?
• The Bayesian network we propose allows refined risk stratification before surgery and is
easily usable.
• Because of its graphical character, the interactions between the different variables
included into the network are directly visualized.
• A prospective feasibility study will be needed prior to implementation in the clinic.
Introduction
In the era of personalized medicine, individualized treatment aims to minimize unnecessary
exposure to therapy-related morbidity and at the same time offer proper management for
high-risk patients. Bayesian networks (BNs) are graphical representations of probability distri-
butions that visualize conditional probabilistic dependence relationships that often can be
given a causal reading. These machine-learning–based computational models are well suited
for prognostication and can be applied even when some patient findings are missing [1]. One
advantage is that they enable to study the influence of all variables on one another, resembling
clinical reasoning more closely than other models.
Although most patients with endometrial carcinoma (EC) present with early-stage disease
and have a favorable prognosis, approximately 89,900 patients around the world died in 2018
as a consequence of this disease [2]. The presence of pelvic and/or para-aortic lymph node
metastasis (LNM) is one of the most important prognostic factors for poor outcome. Identifi-
cation of LNM during primary treatment allows patients to benefit from adequate adjuvant
treatment because adjuvant treatment improves survival in node-positive EC [3,4]. However,
routine lymphadenectomy in clinical early-stage EC has no impact on outcome and is
PLOS MEDICINE Endometrial cancer Bayesian network
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003111 May 15, 2020 3 / 19
associated with substantial long-term morbidity [5,6]. Consequently, no consensus exists
regarding the selection of patients who will benefit from lymphadenectomy. The current
guidelines are suitable to guide lymph-node–directed surgery based on clinicopathological fac-
tors [7]. Yet, approximately 50% of LNM is found in patients designated as low/intermediate
risk, and a recent study showed that diagnostic accuracy for the prediction of LNM could be
improved [8,9]. The introduction of sentinel-lymph–node (SLN) mapping provides a less inva-
sive alternative strategy for evaluating lymph node status with only limited morbidity. How-
ever, this procedure can be particularly challenging in obese patients. Moreover, there is
debate about the impact of non-SLN involvement in pelvic and para-aortic lymph nodes, sup-
porting the need for noninvasive tools discriminating between patients with low risk and those
with extensive nodal involvement [10].
The use of preoperative prediction models could decrease over- and undertreatment and
allow prognosis-based shared decision-making. By identifying low-risk EC groups that do not
need lymph-node–directed surgery, these tools could positively impact healthcare costs. Only
a few models rely exclusively on preoperative data, none have been implemented into current
guidelines, and, to our knowledge, only one performs with an area under the curve (AUC)
above 0.75 for prediction of LNM, highlighting the need for more refined preoperative risk
stratification [11–14]. The Cancer Genome Atlas (TCGA) has demonstrated the prognostic
value of molecular classification in EC, which may be suitable for adjuvant treatment planning
in the future [8,15,16]. So far, these subgroups have not been related to LNM in a preoperative
setting nor to lymph-node–directed surgery. The p53-mutant subgroup was eminently identi-
fied as the subgroup with the poorest outcome and can be easily assessed by immunohis-
tochemistry [17].
We sought to develop and externally validate a preoperative BN based on clinical, histo-
pathological, and molecular biomarkers for the prediction of LNM and disease-specific sur-
vival (DSS) in EC patients.
Methods
Development cohort
A retrospective multicenter study was performed. The patients were identified from a previ-
ously published cohort and included patients treated between February 1995 and August 2013
for International Federation of Gynecology and Obstetrics (FIGO) stage I–IV endometrioid
endometrial carcinoma (EEC) or nonendometrioid endometrial carcinoma (NEEC) at one of
10 participating European Network for Individualized Treatment of Endometrial Cancer
(ENITEC) centers [16]. Participating centers were Radboud University Medical Center, Nij-
megen, the Netherlands; University Medical Center Turku, Finland; KU Leuven, Belgium;
University Hospital Brno, Czech Republic; University Medical Center Freiburg, Germany;
Bichat-Claude Bernard Hospital, Paris, France; Haukeland University Hospital, Bergen, Nor-
way; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Vall Hebron University Hospital,
Barcelona, Spain; and Hospital del Mar, Barcelona, Spain.
Only patients diagnosed by an expert gynecological pathologist, with complete clinical and
pathological data and follow-up of at least 36 months were included, yielding a cohort of 1,199
patients. For the current study, preoperative endometrial biopsy slides were collected for
assessment of the selected molecular biomarkers. This study was approved by the Institutional
Review Board Radboud University Medical Center (Nijmegen, the Netherlands, Institutional
Study Protocol 2015–2101). No informed consent was obtained because all data were analyzed
anonymously. This study is reported as per the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guideline (S1 STROBE Checklist).
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Selection and definition of variables
An overview of study procedures can be appreciated from Fig 1. This plan was constructed
before the study had begun to produce data. Potential preoperative clinical and histopatholog-
ical variables with prognostic value for the prediction of LNM were identified by a systematic
review of the literature (Table 1) [18]. Four validated molecular biomarkers were selected for
immunohistochemical staining on preoperative biopsy samples: estrogen receptor (ER), pro-
gesterone receptor (PR), L1 cell adhesion molecule (L1CAM), and p53. Loss of ER and PR was
validated as independent prognostic markers for the prediction of LNM [8]. From a biological
perspective, loss of ER was associated with epithelial-to-mesenchymal transition (EMT) [19].
L1CAM was validated as a strong prognostic biomarker in EC and was also associated with
EMT [16,20]. Research by TCGA has shown that p53 status identified patients who had an
inherent poor prognosis [15]. Adjuvant therapy was given according to regional or national
protocols. Outcome variables were the presence of pelvic and/or para-aortic LNM, disease
recurrence, and DSS at 1, 3, and 5 years. Disease recurrence was classified as local (vaginal
vault), regional (involving pelvic structures), or distant (other recurrences).
Immunohistochemical analysis of endometrial biopsies
Detailed information on tissue processing, immunohistochemical analysis, and scoring can be
found in S1 Text. ER and PR antibodies were generously provided by Dako (Agilent Technolo-
gies, Santa Clara, CA, USA). Scoring of immunohistochemical staining was performed twice
Fig 1. Summarizing overview of the BN development and validation. BN, Bayesian network; MoMaTEC, Markers for the Treatment of Endometrial Cancer;
PIPENDO, PIpelle Prospective ENDOmetrial carcinoma.
https://doi.org/10.1371/journal.pmed.1003111.g001
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by assessors blinded to pathological and clinical characteristics (N.V., H.K., J.B., K.v.d.V., C.
R.). Discrepancies in scoring were reviewed in a consensus meeting with all assessors.
Bayesian network development
The BN was developed through an iterative process, including stepwise construction of differ-
ent network structures using manual construction and a data-driven approach. First, manual
construction was performed because the use of expert knowledge is known to improve struc-
ture learning processes [21]. Based on systematic review and expert meetings, potential preop-
erative predictors were selected. These variables were displayed by the BN as nodes, and causal
relationships were defined and visualized as arrows connecting the nodes. As a starting point
for the network structure, all variables important for creating a causal network representative
Table 1. Candidate variables for the construction of the BN.
Variables Cutoff value(s)
Preoperative clinical and histopathological variables
Age <70;�70 years
Body mass index <25;�25 kg/m2
Hemoglobin� <12;�12 g/dl
Leukocyte counts� �10 × 109; >10 × 109/l
Thrombocyte counts� <400 × 109; �400 × 109/l
Ca-125 serum levels� <35;�35 IU/ml
Lymphadenopathy on MRI or CT No; yes (�10 mm short axis diameter)
Cervical cytology No; yes (atypical endometrial cells present)
Tumor grade† 1; 2; 3
Tumor histology† Endometrioid; non-endometrioid
Preoperative molecular biomarkers
ER expression <10;�10% of tumor cells with nuclear staining
PR expression <10;�10% of tumor cells with nuclear staining
L1CAM expression <10;�10% of tumor cells with membranous staining
p53 expression Wild type; aberrant‡
Postoperative variables
Myometrial invasion No invasion; <50%;�50%
Lymphovascular space invasion No; yes
Cervical invasion No; yes
FIGO stage IA; IB; II; IIIA; IIIB; IIIC; IV
Tumor grade§ 1; 2; 3¶
Tumor histological subtype§ Endometrioid; nonendometrioid
Adjuvant therapy None; radiotherapy; chemotherapy; chemoradiation; other
�Preoperative serum levels, assessed within 2 weeks before surgery.
†Tumor grade and histology assessed in preoperative endometrial biopsy.
‡Expression was considered aberrant when nuclear staining was completely absent or when more than 80% of tumor
cell nuclei exhibited strong expression.
§Tumor grade and histological subtype assessed in hysterectomy specimens.
¶Grade 3 includes grade 3 EECs and NEECs.
Abbreviations: BN, Bayesian network; Ca-125, cancer antigen 125; CT, computed tomography; EC, endometrial
carcinoma; EEC, endometrioid EC; ER, estrogen receptor; FIGO, International Federation of Gynecology and
Obstetrics; L1CAM, L1 cell adhesion molecule; MRI, magnetic resonance imaging; NEEC, non-endometrioid EC;
PR, progesterone receptor.
https://doi.org/10.1371/journal.pmed.1003111.t001
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of natural tumor progression were included: postoperative tumor grade, myometrial invasion
(MI), and lymphovascular space invasion (LVSI). These variables were, however, not used for
prediction of the outcomes. Subsequently, the selected preoperative predictors were added to
the structure. A likelihood was calculated to determine after each cycle how well the network
fitted the data set. A higher log-likelihood indicates that a model explains a given data set more
accurately.
Second, a data-driven approach using score-based machine learning algorithms was
adopted to further improve the BN. Specifically, the hill-climbing and Tabu-search algorithms
were used. Bootstrap resampling was applied to learn 500 network structures. Arc strengths
(between 0 and 1) were computed, including the frequency of an edge (approximating its clini-
cal significance) between 2 variables across the 500 bootstrap-resampled network structures.
Edges with arc strength > 0.7 were considered for inclusion in the BN. Again, log-likelihood
was used to establish the goodness of fit to the data of the resulting BN model. Multiple impu-
tation was employed to impute missing data. This method calculated missing values by using
all the nodes of the BN as evidence in 500 random samples, which were averaged for each new
observation. The network was developed and imputation was performed using R (3.3.2) with
the bnlearn package (4.4.1).
BN validation
Validation was performed by using only preoperative variables as predictor variables. Network
performance was assessed based on overall performance, calibration, and discrimination test-
ing. The model’s overall performance was quantified by the Brier score, which is the mean
squared difference between each predicted probability and the observed outcome, between 0
and 1. A lower Brier score indicates better accuracy of the probabilistic predictions. Discrimi-
nation was assessed using a receiver operating characteristic (ROC) curve generated by plot-
ting sensitivity against 1-specificity. Discriminative performance was quantified based on the
AUC. Calibration was visualized using calibration plots, in which the predicted outcome was
plotted against the observed outcome. To quantify model calibration, the predicted number of
events was compared with the observed number. Sensitivity analyses were performed by omit-
ting molecular markers and clinical markers, respectively. Finally, decision analysis curves
were plotted to assess the net benefit of BN-assisted decisions.
Performance was validated using 2 prospective multicenter external data sets: the Molecular
Markers in Treatment in Endometrial Cancer (MoMaTEC) cohort (n = 446), including
patients treated between May 2001 and 2010, and the PIpelle Prospective ENDOmetrial carci-
noma (PIPENDO) cohort (n = 384), including patients treated between September 2011 and
December 2013 [8,22]. Patients from these cohorts were only included if they had a minimal
subset of variables: preoperative tumor grade, at least 3 molecular biomarkers, at least one of
the clinical preoperative markers, and information on outcome. The MoMaTEC cohort was
used to validate both outcomes (LNM and 5-year DSS) because all included patients had
undergone lymphadenectomy; the PIPENDO cohort was used to validate 5-year DSS only
because information on LNM was only available for a subset of patients. Analyses were per-
formed using IBM SPSS version 25.0 (SPSS IBM, New York, NY, USA) and R (3.3.2), with the
caTools (1.17.1.2), pROC (1.14.0) and caret packages (6.0–84).
Results
Patients
Preoperative endometrial biopsies were available from 809 of the 1,199 patients (67.4%) in the
development cohort. Subsequently, 46 patients (3.8%) were excluded because of insufficient
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tumor tissue in their endometrial biopsy, leaving 763 patients for analysis (S1 Fig). Baseline
characteristics are shown in Table 2 and did not differ significantly from those of excluded
patients, except for cervical invasion (P = 0.03, S1 Table). The number of missing data for
which imputation was used can be appreciated from Table 2 as well. A total of 215 cases had
information on all predictor variables. The MoMaTEC validation cohort consisted of 446
patients, and the PIPENDO validation cohort of 384 patients (Table 2).
BN development
The final BN is depicted in Fig 2. We elected not to include age, BMI, comorbidity, histology,
hemoglobin, or leukocytes because the arc strengths obtained from machine learning were
<0.7, which was supported by recent systematic reviewing of literature showing only moderate
performance [18]. According to BN construction, all variables that represent natural tumor
progression were included, e.g., LVSI and MI, yet only preoperative variables were used for
prognostication. All probability distributions are shown in the nodes, and dependencies are
indicated by the arrows connecting the nodes. Variables linked to each other are assumed to
be dependent. If variables are not connected directly or indirectly, they are assumed to be inde-
pendent. Also, the direction of the arrows represents causality; e.g., “myometrial invasion!
lymph node metastasis” can be read as “myometrial invasion causes lymph node metastasis.”
Multiple arrows pointing toward the same variable indicate that the variable is the conse-
quence of more than one cause.; e.g., “myometrial invasion! lymph node metastasis” and
“LVSI! lymph node metastasis” represent 2 separate but interacting causes of LNM.
Application of the BN
Probability distributions without input from the other variables are represented in Fig 2A. If
the network is provided with evidence from patient findings, the probability distributions are
automatically updated; e.g., if information about preoperative tumor grade (grade 2), L1CAM-
expression (positive), cervical cytology (atypical endometrial cells present), and cancer antigen
125 (Ca-125) level (elevated) is added, the probability of having LNM increases from 8.6% to
77.7% (Fig 2B). Also, probability estimates of all other variables included in the network can be
extracted; e.g., in this specific situation, the probability of a grade 3 tumor in the hysterectomy
specimens increases from 18.7% to 73.9%, and the probability of LVSI increases from 16.4% to
71.6%.
To further explain the BN’s behavior, S2 Table provides examples of the probability esti-
mates for LNM in different situations. We developed an app-based tool using the BN to esti-
mate the probability of LNM and 5-year DSS in individual patients that will be treated for EC
(concept is shown in Fig 3).
Validation
Validation was performed by using only the preoperative variables as predictor variables. The
AUC was 0.82 (95% confidence interval [CI] 0.76–0.88) for LNM and 0.82 (95% CI 0.77–0.87)
for 5-year DSS in the MoMaTEC cohort (Fig 4). Fig 4 depicts ROC curves compared to ROC
curves obtained from using only classic histopathological markers (tumor grade) as predictor
variables. The Brier scores were 0.09 for LNM and 0.12 for 5-year DSS, respectively. For 5-year
DSS in the PIPENDO cohort, the AUC was 0.84 (95% CI 0.78 to 0.90), and the Brier score was
0.10.
The prediction of LNM was well-calibrated with the observed LNM for the external MoMa-
TEC cohort (Fig 4). The prediction of 5-year DSS was well-calibrated with the observed 5-year
DSS for both external data sets, with a trend toward overestimating survival in the lower
PLOS MEDICINE Endometrial cancer Bayesian network
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Table 2. Baseline characteristics of development cohort and 2 validation cohorts.
Variable Development cohort Validation cohort MoMaTEC Validation cohort PIPENDO
(N = 763) (N = 446) (N = 384)
Age (y) 65 (58–71) 64 (59–74) 66 (60–73)
BMI (kg/m2) 29 (26–33) 27 (24–32) 29 (25–33)
Follow-up (months) 60 (45–74) 54 (28–71) 50 (33–59)
Tumor grade, preoperative
—1 372 (48.8) 182 (47.4)
—2 173 (22.7) 374 (83.9)� 99 (25.8)
—3 110 (14.4) 72 (16.1) 103 (26.8)
—Unknown 108 (14.2)
ER expression
—Positive 686 (89.9) 345 (77.4) 342 (89.1)
—Negative 76 (10.0) 101 (22.6) 41 (10.7)
—Unknown 1 (0.1) 1 (0.3)
PR expression
—Positive 620 (81.3) 335 (75.1) 298 (77.6)
—Negative 137 (18.0) 109 (24.4) 85 (22.1)
—Unknown 6 (0.8) 2 (0.4) 1 (0.3)
L1CAM-expression
—Negative 665 (87.2) 396 (88.8) 328 (85.4)
—Positive 79 (10.4) 32 (7.2) 55 (14.3)
—Unknown 19 (2.5) 18 (4.0) 1 (0.3)
p53 expression
—Wild type 584 (76.5) 218 (48.9) 275 (71.6)
—Mutant 112 (14.7) 66 (14.8) 107 (27.9)
—Unknown 67 (8.8) 162 (36.3) 2 (0.5)
Ca-125
—�35 IU/ml 318 (41.7) 41 (9.2) 221 (57.6)
—>35 IU/ml 90 (11.8) 14 (3.1) 89 (23.2)
—Unknown 355 (46.5) 391 (87.7) 74 (19.3)
Thrombocytes
—<400 × 109/l 557 (73.0) 249 (55.8) 146 (38.0)
—�400 × 109/l 25 (3.3) 29 (6.5) 18 (4.7)
—Unknown 181 (23.7) 168 (37.7) 220 (57.3)
Imaging results
—No lymphadenopathy 460 (60.3) 110 (24.7) 160 (41.7)
—Lymphadenopathy 38 (5.0) 17 (3.8) 26 (6.8)
—Unknown 265 (34.7) 319 (71.5) 198 (51.6)
Cervical cytology
—Normal 406 (53.2) 127 (28.5) 285 (74.2)
—Abnormal 27 (3.5) 62 (13.9) 37 (9.6)
—Unknown 330 (43.3) 257 (57.6) 62 (16.1)
Tumor grade†
—1 317 (41.5) 171 (38.3) 140 (36.5)
—2 289 (37.9) 142 (31.8) 127 (33.1)
—3 157 (20.6) 133 (29.8) 117 (30.5)
Histological subtype†
—EEC 714 (93.6) 367 (82.3) 307 (79.9)
(Continued)
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predicted survival rates. The ratio of predicted/observed cases for LNM was 1.01 (95% CI
0.77–1.32) in the MoMaTEC cohort. The ratio of predicted/observed cases for 5-year DSS was
1.08 (95% CI 0.97 to 1.20) and 1.05 (95% CI 0.95 to 1.17) in the MoMaTEC and PIPENDO
cohorts, respectively.
Table 2. (Continued)
Variable Development cohort Validation cohort MoMaTEC Validation cohort PIPENDO
—NEEC 49 (6.4) 79 (17.7) 77 (20.1)
—Unknown 1 (0.2)
MI
—<50% 477 (62.5) 273 (61.2) 208 (54.2)
—�50% 283 (37.1) 172 (38.8) 176 (45.8)
—Unknown 3 (0.4)
Cervical invasion
—No 591 (77.5) 371 (83.2) 340 (88.5)
—Yes 86 (11.3) 71 (15.9) 44 (11.5)
—Unknown 86 (11.3) 4 (0.9)
FIGO stage
—IA 428 (56.1) 243 (54.5) 197 (51.3)
—IB 196 (25.7) 102 (22.9) 125 (32.6)
—II 51 (6.7) 38 (8.5) 23 (6.0)
—IIIA 20 (2.6) 6 (1.3) 11 (2.9)
—IIIB 4 (0.5) 1 (0.2) 4 (1.0)
—IIIC 43 (5.6) 43 (9.6) 17 (4.4)
—IV 19 (2.5) 12 (2.7) 7 (1.8)
LVSI
—No 435 (57.0) 91 (20.4) 80 (72.9)
—Yes 96 (12.6) 43 (9.6) 104 (27.1)
—Unknown 232 (30.4) 312 (70.0)
Lymph nodes
—Negative 440 (57.7) 394 (88.3) 57 (14.8)
—Positive 53 (6.9) 52 (11.7) 19 (4.9)
—Unknown 270 (35.4) 308 (80.2)
Treatment
—None 415 (54.4) 323 (72.4) 206 (53.6)
—Radiotherapy 283 (37.1) 43 (9.6) 142 (37.0)
—Chemotherapy 38 (5.0) 77 (17.3) 33 (8.6)
—Chemoradiation 26 (3.4) 1 (0.2) 3 (0.8)
—Hormonal 0 (0) 2 (0.4) 0 (0)
—Unknown 1 (0.1)
Continuous variables are presented as median (with IQR).
�Grade 1 and 2 combined.
†Tumor grade and histology assessed in hysterectomy specimen.
Abbreviations: BMI, body mass index; Ca-125, cancer antigen 125; EEC, endometrioid endometrial carcinoma; ER, estrogen receptor; FIGO, international federation
of gynecology and obstetrics; L1CAM, L1 cell adhesion molecule; LVSI, lymphovascular space invasion; MI, myometrial invasion; MoMaTEC, Markers for the
Treatment of Endometrial Cancer; NEEC, non-endometrioid endometrial carcinoma; PIPENDO, PIpelle Prospective ENDOmetrial carcinoma; PR, progesterone
receptor.
https://doi.org/10.1371/journal.pmed.1003111.t002
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The number of positive predictions for different cutoff values is shown in S3 Table, as well
as sensitivity, specificity, positive predictive values (PPVs), and negative predictive values
(NPVs). With the BN, 249 patients (55.8%) were classified as having a risk of LNM <5%, with
a false-negative rate of 1.6%. The false-positive rate for this cutoff was 76%. The network’s pre-
dictions in the MoMaTEC cohort were then categorized into risk groups based on observed
prevalence of LNM (Table 3). Groups were identified as carrying a very low (0%), low (1.8%),
intermediate (17%), high-intermediate (21%), and high (36%) risk of LNM.
To investigate the impact of different predictors, sensitivity analyses were performed,
including only clinical and histological biomarkers (Ca-125, lymphadenopathy on imaging,
cervical cytology, thrombocytosis, and preoperative tumor grade) and molecular and histologi-
cal biomarkers (ER, PR, L1CAM, p53, and preoperative tumor grade), showing negative
impact on discrimination metrics (S4 Table).
Because AUC analysis and calibration plots are unable to evaluate whether prediction mod-
els improve clinical decision-making, decision analysis curves were constructed. The net
Fig 2. Final BN for the prediction of LNM and 5-year DSS. (A.) Probability estimates are shown when no markers were
recorded. (B.) Example of probability estimates in a case with preoperative tumor grade (grade 2), cervical cytology (atypical
endometrial cells present), L1CAM expression (positive), and Ca-125 serum levels (>35 IU/ml). Probability distributions are
shown in the nodes, and dependencies are indicated by the arrows connecting the nodes. If variables are not connected directly or
indirectly, they are assumed to be (conditionally) independent. Often, the direction of the arrows can be given causal meaning. Red
bars indicate that the specific variable is instantiated, i.e., a specific value or evidence is provided. Blue bars in the bar plots indicate
the resulting probabilities of the probability distributions. Because of imputation, probability distributions vary slightly from
Table 2. BN, Bayesian network; Ca-125, cancer antigen 125; DSS, disease-specific survival; LNM, lymph node metastasis; LVSI,
lymphovascular space invasion; L1CAM, L1 cell adhesion molecule.
https://doi.org/10.1371/journal.pmed.1003111.g002
Fig 3. Concept web-based interface of the BN. The baseline probability estimates for LNM and 5-year DSS (visualized in panel A) are interactively updated when
variables are provided to the model (visualized in panel B). BN, Bayesian network; Ca-125; cancer antigen 125; DSS, disease-specific survival; ER, estrogen receptor;
LNM, lymph node metastasis; L1CAM, L1 cell adhesion molecule; PR, progesterone receptor.
https://doi.org/10.1371/journal.pmed.1003111.g003
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Fig 4. ROC curves. (A) Prediction of LNM in the MoMaTEC cohort, (B) prediction of 5-year DSS in the MoMaTEC cohort, and (C) prediction of
5-year DSS in the PIPENDO cohort. Calibration plots for (D) prediction of LNM in the MoMaTEC cohort, (E) prediction of 5-year DSS in the
MoMaTEC cohort, and (F) prediction of 5-year DSS in the PIPENDO cohort. (G) Concordance statistics of the BN. The solid blue lines represent the
ROC curves obtained by ENDORISK. The blue dotted lines represent the ROC curves including obtained by using only preoperative tumor grade as
predictor (as a reference). The vertical bars in panel D represent 95% CIs. AUC, area under the curve; BN, Bayesian network; CI, confidence interval;
DSS, disease-specific survival; ENDORISK, preoperative risk stratification in endometrial cancer; LNM, lymph node metastasis; MoMaTEC, Markers
for the Treatment of Endometrial Cancer; PIPENDO, PIpelle Prospective ENDOmetrial carcinoma; ROC, receiver operating characteristic.
https://doi.org/10.1371/journal.pmed.1003111.g004
Table 3. Risk groups assigned based on predicted probabilities by the ENDORISK BN.
Predicted probability Risk group Observed prevalence LNM in risk group N of patients assigned to risk group
<1% Very low 0/24 (0%) 24/446 (5.4%)
1%–5% Low 4/225 (1.8%) 225/446 (50%)
6%–15% Intermediate 14/84 (17%) 84/446 (19%)
16%–25% High-intermediate 9/43 (21%) 43/446 (10%)
>25% High 25/70 (36%) 70/446 (16%)
Abbreviations: BN, Bayesian network; ENDORISK, preoperative risk stratification in endometrial cancer; LNM, lymph node metastasis.
https://doi.org/10.1371/journal.pmed.1003111.t003
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benefit using preoperative risk stratification in endometrial cancer (ENDORISK) (red lines),
the net benefit made with the assumption that none has the outcome of interest (black lines),
and the net benefit made with the assumption that all have the outcome of interest (gray line)
are shown in S2 Fig. Use of the BN predictions for LNM to inform clinical decisions was better
than a scenario in which all patients were treated or in which no patient was treated, with a
risk probability ranging between 0.05 and 0.55.
Discussion
We have developed and externally validated the ENDORISK BN for EC patients, based on
molecular, histological, and clinical biomarkers, to predict LNM and 5-year DSS. External vali-
dation revealed high discriminative performance and good calibration for both outcomes.
ENDORISK was able to classify 55.8% of the patients as at<5% risk for LNM, with a false-neg-
ative rate of 1.6%.
In the era of “personalized medicine,” the use of prediction models has gained increasing
interest among clinicians to guide treatment planning. Routine lymphadenectomy in clinical
early-stage EC has not been demonstrated to improve outcome and is associated with surgery-
related morbidity of 15% to 20% [6]. However, selective surgery to identify those patients with
LNM in a primary setting is crucial because 5-year survival is 60% to 65% after adjuvant ther-
apy for LNM [3]. The ENDORISK model is based on variables that can be assessed preopera-
tively, and it could therefore support patient counseling and shared decision-making before
surgery. This model informs both the clinician and patient with individualized risk estimates
weighed against patients’ preferences and the extent of the surgical approach. Instead of pro-
viding risk groups, this model presents individualized and continuous risk estimates, with the
potential to improve tailored treatment planning. More specifically, ENDORISK could help to
decide whether to perform lymph-node–directed surgery or support physicians in deciding
whether to perform lymphadenectomy when a side-specific SLN cannot be detected. Using the
model allows identification of a low-risk (<5%) subgroup, with a false-negative rate of 1.6%,
which may lead to selective omission of lymph-node–directed surgery. Acceptable cutoff val-
ues have to be weighed against patients’ preferences, comorbidity, and age. We have shown
that different risk groups can be identified, which could be used to support shared decision-
making in clinical practice. Before implementation in the clinic, prospective evaluation will be
necessary. The mobile application can be easily used in outpatient clinic settings to inform cli-
nicians and patients during clinical decision-making. In this way, ENDORISK can interac-
tively be used requiring not more than a few minutes. Further implementation may be
facilitated by the development of a decision aid tool.
Few attempts have been made to predict the risk of LNM before surgical treatment [11–13].
Koskas and colleagues evaluated the performance of these models within their cohort of 519
patients [11–14]. Only one model had an AUC> 0.75, highlighting the need for improved pre-
operative risk stratification [11]. Integration of molecular classification of EC could improve
risk stratification by providing robust biomarkers that are more reflective of actual tumor biol-
ogy [15]. The “copy-number high” subgroup was eminently identified as the subgroup with
the poorest prognosis and is reflected by abnormal immunohistochemical p53 expression.
Anticipating on the rise of molecular classification this biomarker was included into the BN.
Preoperative ER and PR expression, evaluated in the prospective MoMaTEC1-trial, predict
LNM with an adjusted odds ratio of 2.0 [8]. L1CAM expression, validated as a preoperative
prognostic biomarker, predicts LNM with an adjusted odds ratio of 2.5 and was shown to
refine the “p53wt” subgroup [16,23].
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Our model incorporated both molecular and clinical information and exhibited high diag-
nostic performance in 2 rounds of external validation. Because BNs determine causes and
effects based on the conditional probabilities between variables, they can be used to make
meaningful predictions even when not all variables are available, in contrast to traditional
regression models that require all predictor variables to be known. Moreover, the visual net-
work structure provides interpretable predictions on all variables and allows clinical reasoning
based on intuitive connections between variables in medical data [1].
In an attempt to decrease morbidity associated with lymphadenectomy, a shift is taking
place toward less invasive SLN mapping, which allows evaluation of SLN with only limited
morbidity [24]. Identification of the SLN is successful in 81% of patients, which has led to an
algorithm that prescribed side-specific lymphadenectomy in the event that SLN cannot be
detected in a hemipelvis [24,25]. With the ENDORISK model, we correctly identified 55% of
patients with extremely low risk of LNM, in whom lymph node evaluation might be omitted
in specific cases such as morbidly obese or fragile patients [10]. The exact role of SLN mapping
in high-risk patients, especially with nonendometrioid histology, remains to be elucidated
[26]. Patients with LNM could benefit from surgical removal of metastatic lymph nodes, as a
retrospective study including 12,333 patients showed that the extent of nodal resection signifi-
cantly was associated with improved survival in node-positive patients (53% in patients with
fewer than 10 nodes removed to 72% in those with more than 20 nodes removed) [27]. To
note, this study was unsuited to draw any conclusions on causality. Moreover, uncertainty of
para-aortic node status may result in inappropriate adjuvant therapy choices, including nonin-
clusive radiation fields.
The current study has some limitations. Inherent to the retrospective nature of the study,
missing values were present, and techniques were used to impute the missing data. For the
external validation, imputation was not applied because the nature of BNs allows for missing
predictor variables. Moreover, the clinical applicability of ENDORISK to rare histological sub-
types of ECs, e.g., clear-cell carcinomas or undifferentiated carcinomas, remains uncertain
because these cases constitute only a small subgroup within our cohort. We have chosen to
include p53 expression in the ENDORISK model because abnormal p53 was eminently identi-
fied as the subgroup with the poorest prognosis, and p53 status can be easily assessed with
immunohistochemistry [17]. We have chosen to include immunohistochemical biomarkers to
have this model easily and widespread incorporated in clinical practice.
Dynamic prediction modeling is essential to allow a model to stay up to date with changing
treatments and new biomarkers. One of the advantages of BNs is that they can be updated
with new evidence, allowing them to evolve over time through the incorporation of new data.
They can be updated with new data from variables already included in the BN but also with
information on new candidate biomarkers. With the increasing availability of molecular tech-
niques, the inclusion of these immunohistochemical biomarkers is the first step anticipating
on adding molecular information such as polymerase-ε (POLE) and microsatellite instability
(MSI) status in the future if value is demonstrated in the preoperative setting. Moreover, high-
potential imaging biomarkers could include expert ultrasound and novel structural and func-
tional imaging techniques by MRI.
This study illustrates how BNs can be used for individualizing clinical decision-making in
oncology by incorporating easily accessible and multimodal biomarkers. We developed the
preoperative ENDORISK BN model for patients with EC to predict LNM and 5-year DSS,
using molecular, histological, and clinical biomarkers. External validation revealed high diag-
nostic performance. The network improves understanding of the complex interactions under-
lying the carcinogenetic process of endometrial cancer by its graphical representation. By
applying ENDORISK in a representative endometrial cancer cohort, 55.8% of patients were
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classified as low risk, with a false-negative rate of 1.6% (4/249). To investigate whether
ENDORISK positively impacts individualized treatment, prospective evaluation is necessary
incorporating patient-reported outcome measures.
URL
The ENDORISK BN can be downloaded from http://www.cs.ru.nl/~peterl/endomcancer.
html.
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